British Association of Dermatologists' Guidelines for the Management of Pemphigus Vulgaris 2017

K.E. Harman; D. Brown; L.S. Exton; R.W. Groves; P.J. Hampton; M.F. Mohd Mustapa; J.F. Setterfield; P.D. Yesudian


The British Journal of Dermatology. 2017;177(5):1170-1201. 

In This Article

Further Investigations

The following additional investigations should be considered prior to commencing treatment: full blood count and differential, urea and electrolytes, liver function tests, fasting glucose and glycated haemoglobin (HbA1c), fasting lipids, antinuclear antibody (differential of pemphigus erythematosus), urinalysis, blood pressure, weight, height (children) and a pregnancy test in female patients at risk of pregnancy. Current guidelines on prevention of osteoporosis[30] should be followed, so a bone density scan early in the course of treatment may be needed. In anticipation of using an adjuvant immunosuppressant, appropriate recommended additional investigations and vaccinations should be undertaken. A baseline measure of disease activity (see section 9·1) and quality of life, supplemented by IIF and ELISA titres if facilities exist, will be useful for disease monitoring and judging treatment responses (see sections 9·0–9·2).